Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.12
Previous CloseN/A
Volume2.00
Average Volume (3M)53.81K
Market Cap
$1.29M
Enterprise Value$1.94
Total Cash (Recent Filing)$2.00K
Total Debt (Recent Filing)$520.00K
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding50,297,450
10 Day Avg. Volume113,367
30 Day Avg. Volume53,809
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Oncology PlatformA proprietary RNAi delivery approach gives BPTH a defined technology platform rather than a single undifferentiated drug candidate. If development succeeds, the platform could support multiple oncology programs and create durable strategic value across hematologic and other cancer indications.
Low Absolute DebtVery low absolute debt limits the immediate burden of interest expense and refinancing obligations. That provides some financial flexibility relative to a highly leveraged development-stage biotech, even though the company remains dependent on outside funding and has a weak overall balance sheet.
Reduced Cash BurnThe sharp reduction in annual cash outflow indicates better near-term spending control and extends the usefulness of available resources compared with the prior year. This does not establish self-funding, but a lower burn rate can provide more time to advance programs or secure financing.
Bears Say
No Commercial RevenueBPTH has not yet demonstrated commercial demand or product monetization, leaving its business model dependent on future clinical and regulatory success. The absence of revenue also limits internal funding for research and makes future operating performance highly contingent on candidate development outcomes.
Negative Equity And Asset DeclineNegative equity and a steep reduction in total assets indicate substantial capital depletion and materially weaken financial flexibility. This condition can constrain the company’s ability to fund development internally, increase dependence on new capital, and heighten balance-sheet instability over the next several quarters.
Persistent Operating LossesRecurring large losses and ongoing negative cash generation show that BPTH has not established operating leverage or a sustainable earnings engine. Even with improved 2025 burn, continued reliance on external financing remains necessary to sustain operations and advance its clinical pipeline.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.12 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $1.29M.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 66 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on Aug 18, 2026. The company reported -$0.088 earnings per share for the quarter.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.088 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Technical Analysis
Matinas BioPharma
―
Cellectar Biosciences
―
Moleculin Biotech
―
Nucana
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.50% Other Institutional Investors
99.50% Public Companies and
Individual Investors